Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | July 15, 2024 | July 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date July 15, 2024 · Filed July 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2034-07-15 | Direct | 20,000 |
Reported balance
After 2024-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-15 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000950170-24-084294 · ownership.xml · derivative · entry 1 Spragens Jeffrey G · CIK 0001410620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-07-15 F1 · security: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 14:20 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | OtherWarrants · Derivative | 19,936 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001437749-23-005167 · rdgdoc.xml · derivative · entry 1 Spragens Jeffrey G · CIK 0001410620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,936 Underlying: Common Stock · 19,936 shares Expires 2026-10-20 F1 · kind: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a member of Big Cypress Holdings LLC, and as part of the distribution received 19,936 warrants of the issuer. F1 · price: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a member of Big Cypress Holdings LLC, and as part of the distribution received 19,936 warrants of the issuer. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 14:02 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantWarrant (Common Stock) · Derivative | 82,987 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001209191-22-060442 · doc4.xml · derivative · entry 2 Spragens Jeffrey G · CIK 0001410620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,987 Underlying: Common Stock · 82,987 shares Expires 2027-12-07 F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 14:02 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 82,987 | $1.21 | $99,999.34 |
DisclosureSEC source: 0001209191-22-060442 · doc4.xml · nonDerivative · entry 1 Spragens Jeffrey G · CIK 0001410620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,989 F1 · date: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance. F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:52 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | OtherCommon Stock | 299,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031401 · doc4.xml · nonDerivative · entry 1 Spragens Jeffrey G · CIK 0001410620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,002 F1 · kind: The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. F1 · price: The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:00 UTC | SAB Biotherapeutics, Inc. BCYP · Entity 5816 | PurchaseCommon Stock | 13,000 | $10.07 | $130,910.00 |
DisclosureSEC source: 0001493152-21-024641 · ownership.xml · nonDerivative · entry 1 Spragens Jeffrey G · CIK 0001410620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · kind: Represents 13,000 shares of the issuer's common stock acquired by the reporting person in open market transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.